PMID- 18054475
OWN - NLM
STAT- MEDLINE
DCOM- 20080320
LR  - 20131121
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 78
IP  - 1
DP  - 2008 Jan
TI  - Rationale for adjuvant fatty acid therapy to prevent radiotherapy failure and 
      tumor recurrence during early laryngeal squamous cell carcinoma.
PG  - 21-6
AB  - Information from a preceding lipid study contributed to the pathobiological 
      assessment of laryngeal squamous cell carcinoma (LSCC). Lipid-driven signaling 
      pathways are responsible for laryngeal carcinogenesis and immunodeficiency. The 
      construction of fatty acid (FA) profiles for LSCC allowed the identification of 
      FA role players. The integration of lipid and clinicomolecular information 
      encountered in the literature, in turn, allowed the identification of biological 
      prognostic markers to distinguish between early (less aggressive) and advanced 
      (more aggressive) LSCCs. High arachidonic acid (AA) and cyclooxygenase (COX-2) 
      activities are criteria for less aggressive growth, whilst low AA and COX-2 
      activities occur during more aggressive growth. Excessive tobacco use and 
      environmental smoke or human papillomavirus (HPV) infection and alcohol abuse 
      can, respectively, elicit cumulative oxidative stress and an oxidative burst or 
      interfere with signaling pathways during essential fatty acid (EFA) metabolism, 
      all factors and events which may cause LSCC. Research revealed that enhanced 
      COX-2 activity and Bcl-2 expression prevent apoptosis and, hence, LSCCs become 
      resistant to radiotherapy. It was also observed that recurrent laryngeal cancers 
      become more aggressive after radiotherapy failure. It is predicted that 
      manipulation of AA activity and consequently a cascade of downstream factors that 
      include COX-2 and Bcl-2 expression responsible for LSCC may have therapeutic 
      potential to improve radiotherapy outcome during early LSCC. Adjuvant FA therapy 
      to improve early LSCC management by counteracting radiotherapy failure and 
      unwanted complications for further management is proposed. FA therapeutic 
      strategies before and during radiotherapeutic courses need to be evaluated.
FAU - Louw, L
AU  - Louw L
AD  - Department of Otorhinolaryngology, Faculty of Health Sciences, University of the 
      Free State, Bloemfontein 9300, South Africa. gnanll.md@mail.ouvs.ac.za
FAU - Claassen, J
AU  - Claassen J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20071203
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Fatty Acids)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
SB  - IM
MH  - Apoptosis
MH  - Arachidonic Acid/metabolism
MH  - Carcinoma, Squamous Cell/drug therapy/metabolism/*radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - Cyclooxygenase 2/metabolism
MH  - Fatty Acids/*therapeutic use
MH  - Humans
MH  - Laryngeal Neoplasms/drug therapy/metabolism/*radiotherapy
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
RF  - 71
EDAT- 2007/12/07 09:00
MHDA- 2008/03/21 09:00
CRDT- 2007/12/07 09:00
PHST- 2007/02/28 00:00 [received]
PHST- 2007/09/27 00:00 [revised]
PHST- 2007/10/09 00:00 [accepted]
PHST- 2007/12/07 09:00 [pubmed]
PHST- 2008/03/21 09:00 [medline]
PHST- 2007/12/07 09:00 [entrez]
AID - S0952-3278(07)00136-6 [pii]
AID - 10.1016/j.plefa.2007.10.007 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2008 Jan;78(1):21-6. doi: 
      10.1016/j.plefa.2007.10.007. Epub 2007 Dec 3.